

In re Application of David J. Brayden
Application No. 09/386,266

Atty. Docket No. P26,485-A USA
Tuesday, January 18, 2005
Page 2

Amendments to the Claims

1 to 34. (Canceled).

35. (Currently amended) A method of inducing a T_H1 polarized immune response ~~to an antigen~~, comprising parenterally administering to a subject microparticles comprising at least one antigen entrapped or encapsulated in a biodegradable polymer, wherein said microparticles are sized such that the average diameter of said the microparticles is from about 2.2 µm to about 4.3 µm.

36. (Previously presented) The method of Claim 35, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 µm.

37. (Previously presented) The method of Claim 35, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

38. (Previously presented) The method of Claim 35, wherein the microparticles are formed using a solvent evaporation method.

39. (Currently amended) The method of Claim 35, wherein the at least one antigen comprises a *B. pertussis* antigen.

40. (Previously presented) The method of Claim 35, wherein the parenteral administration is selected from the group consisting of intraperitoneal administration, subcutaneous administration and intramuscular administration.

41. (Currently amended) A vaccine formulation for enhancing a ~~the~~ T_H1 immune response ~~to at least one antigen~~ and adapted for parenteral administration comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of

In re Application of David J. Brayden
Application No. 09/386,266

Atty. Docket No. P26,485-A USA
Tuesday, January 18, 2005
Page 3

microparticles comprising at least one antigen entrapped or encapsulated in a biodegradable polymer, wherein said microparticles are sized such that the average diameter of ~~said~~ the microparticles is from about 2.2 μ m to about 4.3 μ m.

42. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μ m.

43. (Previously presented) The vaccine formulation of Claim 41, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

44. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles are formed using a solvent evaporation method.

45. (Currently amended) The vaccine formulation of Claim 41, wherein the at least one antigen comprises a *B. pertussis* antigen.

46. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles comprise at least 2 subpopulations of microparticles, each subpopulation comprising a different antigen entrapped or encapsulated by a biodegradable polymer.